DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1963)

Multiple Myeloma | Current Treatment | US | 2016

Multiple Myeloma | Current Treatment | US | 2016

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The multiple myeloma therapy market has witnessed considerable advances in recent years. Effective therapies such as Thalomid, Revlimid, Velcade, Pomalyst, and Kyprolis have transformed the treatment of this disease, and the treatment algorithms for multiple myeloma continue to evolve, driven by the 2015 approval of several novel, high-priced therapies with new mechanisms of action. This analysis provides insight on current and anticipated use of approved therapies for multiple myeloma and on hematologist-oncologists’ perception of these therapies.

Already a Client? Log in to access this report.

  • Pub Date: April 2019

Purchase Report

Recent reports:
You may also be interested in: